For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251215:nRSO4755La&default-theme=true
RNS Number : 4755L BSF Enterprise PLC 15 December 2025
15 December 2025
BSF Enterprise PLC
("BSF" or the "Company")
Changes to timetable for proposed Equity Fundraise and Capital Reorganisation
Further to the Company's announcements and despatch of the Notice of General
Meeting on 28 November 2025, the Company provides an update on the proposed
Equity Fundraise and Capital Reorganisation. Capitalised terms in this
announcement have the same meaning as in the Notice of General Meeting, unless
the context indicates otherwise.
Equity Fundraise
As previously announced, the Equity Fundraise is conditional on, inter alia,
the FCA's approval of the Prospectus to be issued by the Company within 180
days from the date of CLN, expiring on 26 May 2026. The Company is seeking
to obtain the approval of the Prospectus before 28 February 2026.
Update on Capital Reorganisation
It is now expected that the record date for the Capital Reorganisation will
take place on or around 26 February 2026, and the expected date for CREST to
be credited with New Ordinary Shares held in uncertificated form (where
applicable) is on or around 27 February 2026.
Full details of the proposed Capital Reorganisation are set out in the Notice
of General Meeting sent to the Shareholders on 28 November 2025. The
Directors' unanimous recommendation for the Shareholders to vote in favour of
the Resolutions is unchanged from that included in the Notice of General
Meeting.
An announcement will be made following the General Meeting to confirm the
status of the Resolutions.
The Company anticipates that the timetable for the proposed Equity Fundraise
and Capital Reorganisation will be as follows:
Expected Timetable of Principal Events
Publication of Notice of General Meeting and Forms of Proxy 28 November 2025
Latest time and date for receipt of Forms of Proxy and CREST Proxy 10.00 a.m. on 15 December 2025
Instructions for the General Meeting
Time and date of the General Meeting 10.00 a.m. on 17 December 2025
Announcement of results of the General Meeting 17 December 2025
Record time and date for Capital Reorganisation 6.00 p.m. on 26 February 2026
Latest time and date for dealing in Existing Ordinary Shares 6.00 p.m. on 26 February 2026
Expected date of Admission and first day of dealings in New Ordinary Shares on 27 February 2026
the Main Market
Expected date CREST accounts are to be credited with New Ordinary Shares in 27 February 2026
uncertificated form
Despatch of definitive certificate for New Ordinary Shares (in certificated By 20 March 2026
form)
END
For more information and the chance to have your questions directly answered
by the management team, please head to our interactive investor hub via:
https://bsfenterprise.com/link/PREaXr (https://bsfenterprise.com/link/PREaXr)
.
For further enquiries, please visit www.bsfenterprise.com
(http://www.bsfenterprise.com) or contact:
BSF Enterprise PLC https://bsfenterprise.com/s/a1f22b (https://bsfenterprise.com/s/a1f22b)
Geoff Baker - Executive Director
Che Connon - CEO & Director
Shard Capital (Broker)
Damon Heath 0207 186 9000
Isabella Pierre 0207 186 9927
ISIN of the Ordinary Shares
is GB00BHNBDQ51.
SEDOL Code is BHNBDQ5.
Subscribe to our news alert service: https://bsfenterprise.com/s/bb9f43
(https://bsfenterprise.com/s/bb9f43)
About BSF Enterprise PLC
BSF Enterprise PLC (BSF) develops and commercialises cutting-edge
tissue-engineered solutions, including lab-grown leather, cultivated meat, and
corneal repair technologies. By leveraging its proprietary scaffold-free
platform, BSF aims to deliver sustainable alternatives to traditional
materials and meet global demand for environmentally responsible innovations.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END MSCGPGWWPUPAGWC
Copyright 2019 Regulatory News Service, all rights reserved